Multiple sclerosis: pharmacogenomics and personalised drug treatment

被引：0
|
作者：
V. Annibali
G. Ristori
S. Cannoni
S. Romano
A. Visconti
A. Ghazaryan
L. Figà Talamanca
M. Salvetti
R. Mechelli
机构：
[1] Ospedale S. Andrea,Department of Neurology and Centro Neurologico Terapia Sperimentale (CENTERS)
[2] University of Rome “La Sapienza”,undefined
来源：
Neurological Sciences | 2006年 / 27卷
关键词：
Pharmacogenomics; Multiple sclerosis; Therapy; Microarrays;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Multiple sclerosis (MS) is a disorder of the central nervous system with an inflammatory and a neurodegenerative component. We do not yet have a definitive therapy for MS. Attempts to develop new treatments are long and costly and should be paralleled by studies aimed at increasing the therapeutic index of the existing treatments, interferon β and glatiramer acetate. Pharmacogenetics and pharmacogenomics may be of use in this respect though their application may not be straightforward, particularly in MS.
引用
收藏
页码：s347 / s349
相关论文
共 50 条
  • [21] Pharmacogenomics of psychiatric drug treatment
    Pickar, D
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 2003, 26 (02) : 303 - +
  • [22] PERSONALISED DOSING OF CLADRIBINE TO TREAT MULTIPLE SCLEROSIS
    Mao, Zhifeng
    Alvarez-Gonzalez, Cesar
    Allen-Philbey, Kimberley
    Mathews, Joela
    Turner, Benjamin P.
    Gnanapavan, Sharmilee
    Marta, Monica
    Baker, David
    Giovannoni, Gavin
    Schmierer, Klaus
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 : A47 - A48
  • [23] DRUG-TREATMENT OF MULTIPLE-SCLEROSIS
    RUDICK, RA
    SCHIFFER, RB
    HERNDON, RM
    SEMINARS IN NEUROLOGY, 1987, 7 (02) : 150 - 159
  • [24] Regular review - Drug treatment of multiple sclerosis
    Polman, CH
    Uitdehaag, BMJ
    BRITISH MEDICAL JOURNAL, 2000, 321 (7259): : 490 - 494
  • [25] Drug Insight: interferon treatment in multiple sclerosis
    Ruth Ann Marrie
    Richard A Rudick
    Nature Clinical Practice Neurology, 2006, 2 : 34 - 44
  • [26] TREATMENT OF MULTIPLE SCLEROSIS - A REVIEW OF DRUG THERAPY
    SCHUMACHER, GA
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1950, 143 (14): : 1241 - 1250
  • [27] TREATMENT IND FOR MULTIPLE-SCLEROSIS DRUG
    NIGHTINGALE, SL
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (08): : 974 - 974
  • [28] Drug Insight: interferon treatment in multiple sclerosis
    Marrie, RA
    Rudick, RA
    NATURE CLINICAL PRACTICE NEUROLOGY, 2006, 2 (01): : 34 - 44
  • [29] Pharmacogenomics of multiple sclerosis: Association of immune response gene polymorphisms with copaxone treatment efficacy
    E. Yu. Tsareva
    O. G. Kulakova
    O. Yu. Makarycheva
    A. N. Boyko
    S. G. Shchur
    N. Yu. Lashch
    N. F. Popova
    E. I. Gusev
    V. V. Bashinskaya
    D. V. Lvov
    A. V. Favorov
    M. F. Ochs
    O. O. Favorova
    Molecular Biology, 2011, 45 : 886 - 893
  • [30] Pharmacogenomics of multiple sclerosis: Association of immune response gene polymorphisms with copaxone treatment efficacy
    Tsareva, E. Yu.
    Kulakova, O. G.
    Makarycheva, O. Yu.
    Boyko, A. N.
    Shchur, S. G.
    Lashch, N. Yu.
    Popova, N. F.
    Gusev, E. I.
    Bashinskaya, V. V.
    Lvov, D. V.
    Favorov, A. V.
    Ochs, M. F.
    Favorova, O. O.
    MOLECULAR BIOLOGY, 2011, 45 (06) : 886 - 893
12345